Our Pipeline

Affibody has a broad pipeline based on the Affibody^® technology with multiple clinical assets.

Radiopharmaceuticals

Despite advances in cancer therapies, many solid tumors remain difficult to treat. Many existing therapies for cancer are also nonselective and as a result can damage vital organs. Targeted radiopharmaceuticals are designed to bind cancer cells specifically, often enabling higher doses of radiation to reach the tumor while reducing the risk of side effects compared to traditional radiotherapy and chemotherapy. In addition, targeted radiopharmaceuticals can bind to cancer cells that have metastasized to other parts of the body, that traditional radiation therapy may not be able to reach. Targeted radiopharmaceuticals can be tailored to specific cancer types and even individual patients, leading to more personalized and effective treatment approaches.  The Affibody^® platform is uniquely suited for radiotherapy applications and Affibody is developing a pipeline of novel targeted radiopharmaceuticals.

Immunology

Autoimmunity can cause a wide range of diseases and is usually triggered by multiple factors in a biological response that is influenced by highly potent signaling molecules. There is an intense focus on the development of new therapies to counteract these types of harmful processes. Drugs in this field should ideally be able to completely and selectively block the signaling pathways that cause inflammation. Affibody’s unique technology platform is well suited to generate such drugs.